Form 4: Tarsus Pharmaceuticals Executive Wahl Bryan Reports Stock Transactions
SEC Form 4
General Counsel Wahl Bryan of Tarsus Pharmaceuticals reports the vesting and settlement of restricted stock units and shares acquired through the employee stock purchase plan.
Summary
- On March 15, 2025, Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, reported transactions involving the company's stock.
- These transactions included the vesting and settlement of 19,213 restricted stock units (RSUs) into common stock.
- Wahl also reported owning 61,398 shares of common stock, which includes 1,234 shares acquired through the Employee Stock Purchase Plan on June 30, 2024.
- The reported transactions also detail the number of RSUs beneficially owned following the reported transactions.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The vesting of RSUs may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| March 9, 2022 | RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2023. |
| March 8, 2023 | RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2024. |
| June 30, 2024 | 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| March 7, 2024 | RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, vesting 25% annually starting March 15, 2025. |
| March 15, 2025 | Reported transaction date for RSU vesting and settlement. |
| March 18, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.